Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 4,161
Out of 5,241 analysts
57
Total ratings
30.61%
Success rate
-28.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELTX Elicio Therapeutics | Initiates: Buy | $20 | $10.63 | +88.15% | 1 | Apr 15, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.73 | +131.21% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $40 | $3.49 | +1,046.13% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $6.23 | +76.57% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $28.78 | +7.71% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.42 | +1,238.03% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $12.31 | +70.59% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.86 | +168.82% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.77 | +803.95% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.19 | +64,555.17% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $25 | $28.79 | -13.16% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $53.78 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,000 | $3.31 | +302,014.80% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.29 | +442.64% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.72 | +111.86% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.14 | +426.32% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.03 | +148.14% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.83 | +13,014.75% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $1.83 | +9,845.36% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.96 | +67,467.57% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.74 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $11.04 | +90.22% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $5.79 | +181,247.15% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.06 | +1,696.12% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $70.62 | +324.81% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $698.25 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $95.31 | -6.62% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $158.42 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.30 | +25,746.15% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.77 | +378.09% | 1 | Mar 19, 2020 |
Elicio Therapeutics
Apr 15, 2026
Initiates: Buy
Price Target: $20
Current: $10.63
Upside: +88.15%
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.73
Upside: +131.21%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $40
Current: $3.49
Upside: +1,046.13%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.23
Upside: +76.57%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $28.78
Upside: +7.71%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.42
Upside: +1,238.03%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $12.31
Upside: +70.59%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.86
Upside: +168.82%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.77
Upside: +803.95%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.19
Upside: +64,555.17%
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $28.79
Upside: -13.16%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $53.78
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $10,000
Current: $3.31
Upside: +302,014.80%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.29
Upside: +442.64%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $4.72
Upside: +111.86%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.14
Upside: +426.32%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.03
Upside: +148.14%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.83
Upside: +13,014.75%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $1.83
Upside: +9,845.36%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.96
Upside: +67,467.57%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $9.74
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $11.04
Upside: +90.22%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $5.79
Upside: +181,247.15%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.06
Upside: +1,696.12%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $70.62
Upside: +324.81%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $698.25
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $95.31
Upside: -6.62%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $158.42
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.30
Upside: +25,746.15%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.77
Upside: +378.09%